Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that Ingrezza (valbenazine) provided meaningful and sustained benefits for patients ...

M&T Bank Corp lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 23.4% in the fourth ...

This revision follows the company's announcement that Ingrezza, its flagship product ... For more information see our T&C.

But don't stop taking your medicine on your own ... Deutetrabenazine (Austedo) Valbenazine (Ingrezza) Your doctor may also use an off-label medicine called tetrabenazine (Xenazine).

Meanwhile, the pharmacological pipeline for Tourette's is thin, with disappointing results for Teva's deutetrabenazine and Neurocrine Bio's Ingrezza (valbenazine) in phase 3 trials. At the moment ...

JPMorgan lowered the firm’s price target on Neurocrine (NBIX) to $183 from $191 and keeps an Overweight rating on the shares. The firm updated ...

INGREZZA and CRENESSITY, advancing our expanding R&D pipeline and returning capital to shareholders." For More Such Health News, visit rttnews.com. The views and opinions expressed herein are the ...